These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 24446693)

  • 1. Viral suppression in HIV studies: combining times to suppression and rebound.
    Gouskova NA; Cole SR; Eron JJ; Fine JP
    Biometrics; 2014 Jun; 70(2):441-8. PubMed ID: 24446693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Considerations in choosing a primary endpoint that measures durability of virological suppression in an antiretroviral trial.
    Gilbert PB; Ribaudo HJ; Greenberg L; Yu G; Bosch RJ; Tierney C; Kuritzkes DR
    AIDS; 2000 Sep; 14(13):1961-72. PubMed ID: 10997401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empirical power for distribution-free tests of incomplete longitudinal data with applications to AIDS clinical trials.
    Kuhn AM; DeMasi RA
    J Biopharm Stat; 1999 Aug; 9(3):401-16. PubMed ID: 10473028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure time analysis of HIV vaccine effects on viral load and antiretroviral therapy initiation.
    Gilbert PB; Sun Y
    Biostatistics; 2005 Jul; 6(3):374-94. PubMed ID: 15831584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling clinical endpoints as a function of time of switch to second-line ART with incomplete data on switching times.
    Johnson BA; Ribaudo H; Gulick RM; Eron JJ
    Biometrics; 2013 Sep; 69(3):732-40. PubMed ID: 23862631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial.
    Kuhn L; Coovadia A; Strehlau R; Martens L; Hu CC; Meyers T; Sherman G; Hunt G; Persaud D; Morris L; Tsai WY; Abrams EJ
    Lancet Infect Dis; 2012 Jul; 12(7):521-30. PubMed ID: 22424722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should we now adopt the HIV-RNA < 50 copy endpoint for clinical trials of antiretroviral-experienced as well as naive patients?
    Hill A; Miralles D; Vangeneugden T; Lefebvre E
    AIDS; 2007 Jul; 21(12):1651-3. PubMed ID: 17630565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings.
    Chang LW; Harris J; Humphreys E
    Cochrane Database Syst Rev; 2010 Apr; (4):CD008494. PubMed ID: 20393969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brief Report: Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials.
    Treasure GC; Aga E; Bosch RJ; Mellors JW; Kuritzkes DR; Para M; Gandhi RT; Li JZ
    J Acquir Immune Defic Syndr; 2016 Jul; 72(3):310-3. PubMed ID: 26910502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment.
    Bratt G; Karlsson A; Leandersson AC; Albert J; Wahren B; Sandström E
    AIDS; 1998 Nov; 12(16):2193-202. PubMed ID: 9833861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication.
    Ioannidis JP; Havlir DV; Tebas P; Hirsch MS; Collier AC; Richman DD
    AIDS; 2000 Jul; 14(11):1481-8. PubMed ID: 10983634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting.
    d'Arminio Monforte A; Gianotti N; Cozzi-Lepri A; Pinnetti C; Andreoni M; di Perri G; Galli M; Poli A; Costantini A; Orofino G; Maggiolo F; Mazzarello G; Celesia BM; Luciani F; Lazzarin A; Sighinolfi L; Rizzardini G; Bonfanti P; Perno CF; Antinori A;
    Antivir Ther; 2014; 19(3):319-24. PubMed ID: 24036891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral suppression and viral rebound among young adults living with HIV in Canada.
    Palmer A; Gabler K; Rachlis B; Ding E; Chia J; Bacani N; Bayoumi AM; Closson K; Klein M; Cooper C; Burchell A; Walmsley S; Kaida A; Hogg R;
    Medicine (Baltimore); 2018 Jun; 97(22):e10562. PubMed ID: 29851775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV DNA loads, plasma residual viraemia and risk of virological rebound in heavily treated, virologically suppressed HIV-infected patients.
    Gianotti N; Canducci F; Galli L; Cossarini F; Salpietro S; Poli A; Nozza S; Spagnuolo V; Clementi M; Sampaolo M; Ceresola ER; Racca S; Lazzarin A; Castagna A
    Clin Microbiol Infect; 2015 Jan; 21(1):103.e7-103.e10. PubMed ID: 25636935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporating durability information in the comparison of proportions of patients with HIV suppression.
    Chen YH; Nessly ML; Thiyagarajan B
    J Biopharm Stat; 2004 Aug; 14(3):741-55. PubMed ID: 15468762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidrug-resistant HIV viral rebound during early syphilis: a case report.
    Giacomelli A; Micheli V; Cattaneo D; Mancon A; Gervasoni C
    BMC Infect Dis; 2020 Apr; 20(1):273. PubMed ID: 32264923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study).
    Castagna A; Muccini C; Galli L; Bigoloni A; Poli A; Spagnuolo V; Nozza S; Racca S; Galli A; Cinque P; Carini E; Lazzarin A
    J Antimicrob Chemother; 2019 Jul; 74(7):2039-2046. PubMed ID: 31225610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design issues in initial HIV-treatment trials: focus on ACTG A5095.
    Ribaudo HJ; Kuritzkes DR; Schackman BR; Acosta EP; Shikuma CM; Gulick RM
    Antivir Ther; 2006; 11(6):751-60. PubMed ID: 17310819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir.
    Kempf DJ; Rode RA; Xu Y; Sun E; Heath-Chiozzi ME; Valdes J; Japour AJ; Danner S; Boucher C; Molla A; Leonard JM
    AIDS; 1998 Mar; 12(5):F9-14. PubMed ID: 9543434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.